ABC | Volume 115, Nº1, Julho 2020

Artigo Original Macedo et al. Hipertensão resistente em afrodescendentes Arq Bras Cardiol. 2020; 115(1):31-39 1. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58. 2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNAGuideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Pr. Hypertension. 2018 Jun;71(6):e13–115. 3. MalachiasM,SouzaW,PlavnikF,RodriguesC,BrandãoA,NevesM.VIIDiretriz BrasileiraDeHipertensãoArterial.ArqBrasCardiol.2016;107(3Supl.3):1–83. 4. ManciaG,FagardR,NarkiewiczK,Redon J,ZanchettiA,BöhmM,etal.2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. 5. Departamento de Hipertensão Arterial da Sociedade Brasileira de Cardiologia. I Posicionamento Brasileiro Sobre Hipertensão Arterial Resistente. Arq Bras Cardiol. 2012;99(1):576–85. 6. TanjaDudenbostel*,MohammedSiddiqui,NitinGharpureADAC.Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;21(2):129–39. 7. CalhounDA,BoothJN,OparilS,IrvinMR,ShimboD,LacklandDT,etal.Refractory Hypertension:DeterminationofPrevalence,RiskFactors,andComorbiditiesina Large,Population-BasedCohort.Hypertension.2014;63(3):451–8. 8. Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14(1):7–12. 9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement FromtheAmericanHeartAssociationProfessionalEducationCommitteeofthe CouncilforHighBloodPressureResearch.Circulation.2008;117(25):e510–26. 10. Sarganas G, Neuhauser HK. Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008-2011. J Clin Hypertens. 2016;18(11):1146–54. 11. Judd E, Calhoun DA. Apparent and true resistant hypertension: Definition, prevalence and outcomes. J HumHypertens. 2014;28(8):463–8. 12. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: What the cardiologist needs to know. Eur Heart J. 2015;36(40):2686–695c. 13. Dudenbostel T. Resistant hypertension - Complex mix of secondary causes and comorbidities. J HumHypertens. 2014;28(1):1–2. 14. DudenbostelT,AcelajadoMC,PisoniR,LiP,OparilS,CalhounDA.Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33. 15. SiddiquiM,CalhounDA.Refractoryversusresistanthypertension.CurrOpin Nephrol Hypertens. 2017;26(1):14–9. 16. Modolo R, De Faria AP, Sabbatini AR, Barbaro NR, Ritter AMV, Moreno H. Refractory and resistant hypertension: Characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9(5):397–402. 17. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, et al. Management of high blood pressure in blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800. 18. Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: Risk factors, subclinical atherosclerosis, and comorbidities among adults-the brazilian longitudinal study of adult health (ELSA-Brasil). J Clin Hypertens. 2015;17(1):74–80. 19. Boolani H, Sinha A, Randall O. Resistant Hypertension. Curr Cardiovasc Risk Rep. 2013;7(5):354–63. 20. Mente A, O’Donnell MJ, Rangarajan S, McQueenMJ, Poirier P, Wielgosz A, et al. Association of Urinary Sodium and Potassium Excretion with Blood Pressure. N Engl J Med. 2014;371(7):601–11. 21. Grim CE, Grim CM. Omron HEM-711 DLX home Blood pressure monitor passes the European Society of Hypertension International Validation Protocol. Blood Press Monit. 2008 Aug;13(4):225–6. 22. Vera-Cala LM, Orostegui M, Valencia-Angel LI, López N, Bautista LE. Precisão do Aparelho Omron HEM-705 CP na Medida de Pressão Arterial emGrandes Estudos Epidemiológicos. Arq Bras Cardiol. 2011;96(5):393–8. 23. Cockcroft DW& Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. 24. Napoli Filho MDi, Burmeister JE, Miltersteiner R, Machado B, Generali M. Estimativa da Função Renal pela Fórmula de Cockcroft eGault emPacientes com Sobrepeso ou com Obesidade Estimation of Renal Function by the Cockcroft and Gault Formula in Overweighted or Obese Patients. J Bras Nefrol. 2008;30(3):185–91. 25. Oliveira-Filho AD, Barreto-Filho JA, Neves SJF, Lyra Junior DP de. Relação entre a Escala de Adesão Terapêutica de oito itens de Morisky (MMAS-8) e o controle da pressão arterial. Arq Bras Cardiol. 2012;99(1):649–58. 26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of A Madication AdherenceMeasure in anOutpatient Setting. J ClinHypertens. 2008;10(5):348–54. 27. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistanthy pertension:Noveldistinctivephenotypes.JNatSci. 2017;3(9):1–6. 28. CushmanWC, Ford CE, Cutler J a, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404. 29. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. 30. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012–21. 31. Holmqvist L, BoströmKB, Kahan T, Schiöler L, Hasselström J, Hjerpe P, et al. Prevalence of treatment-resistant hypertension and important associated factors—results from the Swedish Primary Care Cardiovascular Database. J Am Soc Hypertens. 2016;10(11):838–46. 32. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902. 33. Václavík J, Sedlák R, PlachýM, Navrátil K, Plášek J, Jarkovský J, et al. Addition ofspironolactone inpatientswithresistantarterialhypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75. 34. Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimaltreatmentfordrug-resistanthypertension(PATHWAY-2):Arandomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. 35. Grassi G, Bombelli M, Seravalle G, Brambilla G, Dell’Oro R, Mancia G. Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hypertens Rep. 2013;15(3):232–7. Referências 38